Regulatory Clash as Online Peptide Craze Outpaces Science
TL;DR
The online hype around MOTS-c and other peptides has spawned unregulated use with little human safety data; researchers press for quality-controlled, prescriber-supervised compounding as a safer alternative to the black market, while FDA staff warn against it due to safety gaps; an FDA panel narrowly backed allowing six peptides to be manufactured via compounding—sparking a policy fight over access, safety, and the future of peptide therapies.
Topics:businesssciencehealth-policy#compounding-pharmacies#fda#mots-c#peptides#regulation#sciencehealth-policy
- From mice to ‘gym rats’: Unregulated use of peptides raises alarm among researchers Los Angeles Times
- What would it take to get peptides on the shelf? NPR
- On Peptides, FDA Staff Scientists At Odds With Advisory Panel Forbes
- ‘I would never do this’: What scientists want you to know about peptide injections sfchronicle.com
- 'It Was a Crazy Risk': Why the Potential Peptide Boom Might Be Like the Rise of Airbnb, Uber Athletech News
Want the full story? Read the original reporting
Read on Los Angeles Times